Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study
Table 3
Maternal and perinatal pregnancy complications in all study pregnancies.
Total
SLE-aPL
SLE + aPL
SLE + APS
value
Maternal complications
Mild HD
21/144 (14.6)
18/117 (15.4)
1/14 (7.1)
2/13 (15.4)
0.82
Severe HD
26/144 (18.1)
19/117 (16.2)
3/14 (21.4)
4/13 (30.8)
0.32
Preeclampsia
24/140 (17.1)
18/113 (15.9)
3/14 (21.4)
3/13 (23.1)
0.82
Onset preeclampsia < 34 weeks
8/24 (33.3)
7/18 (38.9)
1/3 (33.3)
0 (0)
1.00
Eclampsia
1/139 (0.7)
1/112 (0.9)
0/14 (0)
0/13 (0)
1.00
HELLP syndrome
7/144 (4.9)
3/117 (2.6)
1/14 (7.1)
3/13 (23.1)
<0.01
Perinatal complications
IUFD
6/147 (4.1)
6/119 (5.0)
0/15 (0)
0/13 (0)
1.00
Preterm birth (<37 weeks)
48/147 (32.7)
40/119 (33.6)
4/15 (26.7)
4/13 (30.8)
0.95
SGA infant
21/142 (14.8)
18/115 (15.7)
2/15 (13.3)
1/12 (8.3)
0.77
Neonatal lupus
2/147 (1.4)
2/119 (1.7)
0/15 (0)
0/13 (0)
1.00
Data depicted as numbers (%). There were three twin pregnancies. SLE: systemic lupus erythematosus; aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; mild HD: hypertensive disorders of pregnancy including pregnancy induced hypertension; severe HD: hypertensive disorders of pregnancy including preeclampsia, eclampsia, and HELLP (hemolysis, elevated liver enzyme, and low platelet count syndrome); IUFD: intrauterine fetal death; SGA: small-for-gestational age (birth weight < p10).
